Search clinical trials for: Lanifibranor

Total 6 results

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

A Pharmacokinetic Study of Lanifibranor in Healthy Adult Chinese Subjects

Pharmacokinetic

China
Inventiva Pharma

Recruiting

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) (NATiV3)

NASH - Nonalcoholic Steatohepatitis

United States, Argentina, Australia, Austria, Belgium, France, Germany, Israel, Portugal, Spain, United Kingdom, Canada, Italy, China, Brazil, Netherlands, Hungary, Bulgaria, Chile, Czechia, Mexico, Poland, Puerto Rico, South Africa, Uk...
Inventiva Pharma

Completed

Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis (FASST)

Scleroderma, Diffuse | Diffuse Cutaneous Systemic Sclerosis

United Kingdom, France, Spain, Switzerland, Italy, Slovenia, Netherlands, Germany, Bulgaria, Poland
University of Florida
Inventiva Pharma

Completed

Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease

Nonalcoholic Fatty Liver Disease (NAFLD) | Type 2 Diabetes (T2DM)

United States
Inventiva Pharma

Active, not recruiting

Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus (LEGEND)

Diabetes Mellitus, Type 2 | NASH - Nonalcoholic Steatohepatitis

United States, Belgium, France, Netherlands, United Kingdom
Inventiva Pharma
Parexel

Completed

Multiple Ascending Dose Phase I Study in Order to Define Lanifibranor (IVA337) Supra-thjerapeutic Dose (MAD)

Healthy Subjects

Germany

Search clinical trials for: Lanifibranor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Papua New Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations